Should red blood cell transfusion be immediately given to a cirrhotic patient with active upper gastrointestinal bleeding?

Zhaohui Bai¹,², Xiaozhong Guo¹#, Hongyu Li¹, Xiaonan Yu³, Jiao Deng⁴, Man-Fung Yuen⁵, Fernando Gomes Romeiro⁶, Sien-Sing Yang⁷, Jean-Pierre Allain⁸, Xingshun Qi¹; written on behalf of AME Liver Disease Collaborative Group

¹Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, China; ²Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110840, China; ³Department of Transfusion, ³Department of Pharmacy, General Hospital of Shenyang Military Area, Shenyang 110840, China; ⁴Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China; ⁵Botucatu Medical School, UNESP – Universidade Estadual Paulista, São Paulo State, Brazil; ⁶Liver Unit, Cathay General Hospital, Fu-Jen Catholic University School of Medicine, Taipei 10630, Taiwan; ⁷Department of Haematology, University of Cambridge, Cambridge, UK

#These authors contributed equally to this work.

Correspondence to: Dr. Xingshun Qi, MD; Prof. Hongyu Li. Department of Gastroenterology, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang 110840, China. Email: xingshunqi@126.com; 13309887041@163.com.

Abstract: Upper gastrointestinal bleeding (UGIB) is a common complication in patients with cirrhosis and a leading cause of death. Blood transfusion is often required. In this paper, we demonstrated that a cirrhotic case developed repeated hematemesis followed by blood transfusion and discussed the timing of blood transfusion for active variceal hemorrhage.

Keywords: Upper gastrointestinal bleeding (UGIB); variceal; transfusion; cirrhosis; liver

Introduction

Upper gastrointestinal bleeding (UGIB), mainly including variceal and non-variceal bleeding, can lead to a mortality of 2–15% (1). Transfusion of packed red blood cell (PRBC) is often required for the management of acute UGIB (2). Traditionally, if a patient presents with active UGIB, blood transfusion is immediately prescribed by the physicians. However, the appropriateness of this strategy remains uncertain. Herein, we attempted to discuss the optimal window of blood transfusion by showing a cirrhotic patient with acute UGIB who developed repeated hematemesis followed by blood transfusion.

Case presentation

At 11:30 on February 27, 2018, a 57-year-old male was admitted to our department due to intermittent hematemesis and melena for about 12 days. He had a history of hepatitis B virus infection for 20 years and liver cirrhosis for 10 years. He underwent an endoscopic examination at his local hospital on February 11, 2018, which showed the evidence of esophageal varices with a maximum diameter of about 6 mm with a positive red-color sign and gastric varices, but did not undergo endoscopic therapy. He underwent contrast-enhanced computed tomography (CT) scans at his local hospital on February 22, 2018, which showed liver cirrhosis, ascites, and gastroesophageal varices (Figure 1), splenomegaly, a mass in the right hepatic lobe, portal vein tumor thrombosis (Figure 2), a fistula from hepatic artery to portal vein, and an ascending colonic wall swelling. Immediately after the present admission, he developed hematemesis with fresh blood of approximately 600 mL in volume. At that time, blood pressure was 110/87 mmHg, heart rate was 87 b.p.m., and oxyhemoglobin saturation was 100%. Laboratory tests demonstrated that red blood cell (RBC) was 3.27×10¹²/L (reference range: 3.8–5.1×10¹²/L), hemoglobin (Hb) was 128 g/L (reference range: 115–
150 g/L), hematocrit (HCT) was 30.3% (reference range: 35–45%), prothrombin time (PT) was 14.4 s (reference range 11.5–14.5 s), and international standardization ratio (INR) was 1.14. PRBC 3 U and fresh frozen plasma 230 mL were urgently infused and terlipressin, somatostatin, esomeprazole, and ceftriaxone sodium were intravenously given. An urgent endoscopy was refused.

At 15:37 on February 27, 2018, he developed hematemesis again with fresh blood of approximately 600 mL in volume. He remained conscious, and blood pressure was 118/76 mmHg, heart rate was 86 b.p.m., and oxyhemoglobin saturation was 100%. Laboratory tests demonstrated that white blood cell (WBC) was 6.7×10⁹/L (reference range: 3.5–9.5×10¹²/L), percentage of granulocyte (GR%) was 89.6%, RBC was 2.39×10¹²/L, Hb was 74 g/L, HCT was 22.1%, total bilirubin (TBIL) was 13.3 umol/L (reference range: 5.1–22.2 umol/L), direct bilirubin (DBIL) was 7.5 umol/L (reference range: 0–8.6 umol/L), alanine amino-transaminase (ALT) was 42.71 U/L (reference range: 9–50 U/L), aspartate amino-transaminase (AST) was 32.13 U/L (reference range: 15–40 U/L), alkaline phosphatase (AKP) was 115.83 U/L (reference range: 45–125 U/L), γ-glutamyl transpeptidase (GGT) was 209.10 U/L (reference range: 10–60 U/L), and albumin (ALB) was 30.5 g/L (reference range: 40–55 g/L). Child-Pugh score was 7 points. Except for terlipressin, somatostatin, esomeprazole, and ceftriaxone sodium, PRBC 3 U and fresh frozen plasma 270 mL were prescribed again.

At 19:10 on February 27, 2018, he developed hematemesis again with a volume of fresh blood vomited of approximately 200 mL. PRBC 3 U was prescribed again.

At 2:45 on February 28, 2018, he had hematemesis again with a volume of fresh blood vomited of approximately 100 mL. PRBC 2 U was prescribed again.

At 5:00 on February 28, 2018, he had hematemesis again with a volume of fresh blood vomited of approximately 200 mL. Laboratory tests demonstrated that WBC was 14.6×10⁹/L, GR% was 88.6%, RBC was 2.47×10¹²/L, Hb was 77 g/L, HCT was 23.1%, and PLT was 97×10⁹/L. PRBC 3.1 U was prescribed again.

After that, the patient did not develop hematemesis again. On March 6, 2018, he underwent elective endoscopy and was treated with esophageal variceal band ligation. His condition was gradually improved (Figure 3).

**iMDT discussion**

**Discussion among physicians from the General Hospital of Shenyang Military Area**

Because acute UGIB will lead to a decrease of tissue perfusion after acute blood loss (3,4), the infusion of PRBC is often required. However, the timing of blood transfusion is still controversial. A UK study suggested that patients with acute UGIB who received blood transfusions had more frequent re-bleeding than matched patients who did not receive blood products and had a tendency towards increased mortality (5). A randomized controlled trial showed that “restrictive” transfusion (the hemoglobin threshold for transfusion was 7 g/L with a target range for the post-transfusion hemoglobin level of 7–9 g/L) significantly reduced the mortality compared with “liberal” transfusion (the hemoglobin threshold for transfusion was 9 g/L with a target range for the post-transfusion hemoglobin level of 9–11 g/L) (6). In 2013, a meta-analysis showed that restrictive transfusion could significantly decrease the incidence of death in patients with UGIB (7). Recently, a
meta-analysis also suggested that a restrictive transfusion strategy should be associated with a reduction in mortality and re-bleeding in patients with acute UGIB (8). However, in geriatric patients, liberal transfusion strategies might produce better outcomes than restrictive transfusion strategies (9).

Currently, the American Association for the Study of Liver Diseases (AASLD) guideline recommends a restricted infusion of PRBC for patients with variceal bleeding (2). The Baveno VI consensus proposes that the target of Hb for infusion of PRBC should be 70–80 g/L (10). The 2015 UK guideline also suggests either excessive or insufficient blood transfusions leads to adverse events. As for patients with stable hemodynamics, the target of Hb should be adjusted to 70–80 g/L (11). The Chinese guideline also suggests that blood transfusion is required when Hb is less than 60–70 g/L (12).

Our patient had a Hb level of 99 g/L at the time of first hematemesis, which was higher than the threshold for a restrictive transfusion strategy (70 g/L). However, considering that UGIB was active, blood transfusion was prescribed. Unfortunately, he experienced repeated hematemesis followed by blood transfusion. Active UGIB did not appear until his Hb declined to a relatively low level. Thus, a liberal transfusion as a potential cause of repeated hematemesis should not be excluded.

Several issues regarding the management of this patient were further discussed as follows.

**Should RBC transfusion be immediately given to a cirrhotic patient with active UGIB?**

**Expert opinion 1**

In cirrhotic patients, a more liberal approach may be adopted especially in situations when there are derangement of clotting profile and thrombocytopenia.

**Expert opinion 2**

For most patients, I wait for the hemoglobin value, but it depends on the patient conditions, as well as the time span for receiving the blood test result. Some authors have suggested that massive bleeding could be treated by emergency transfusions (13). However, there is no clinical evidence to support this recommendation, probably because it would be difficult to include patients with severe bleeding in clinical trials. Another problem is the definition of massive bleeding, which is not clear. For practical purposes, I suggest to prepare PRBC when the patient has clinical signs of hemorrhagic shock, because in this situation it would be reasonable to begin the transfusion before the hemoglobin result. On the other hand, if the patient has no signs of hemorrhagic shock, I would wait for the lab test.

**Expert opinion 3**

Blood transfusion is not necessary immediately at the timing of acute variceal hemorrhage. The case had a blood pressure of 118/76 mmHg and heart rate of 86 b.p.m. It means...
that the patient is not under life-threatening hypotension. Emergent blood transfusion is not necessary. However, the vital signs should be closely monitored. Blood should be prepared in case of emergency.

**Expert opinion 4**

In my view, this is a case of massive bleeding, irrespective of its cause and, rather than PRBC, fresh whole blood would be indicated. Fresh whole blood is meant as whole blood less than 1-week storage but if possible less than 24 h kept at room temperature. This product is routinely used in West Africa where cirrhosis massive bleeding is frequent and related to the high frequency of chronic hepatitis B. This product has been promoted by the American surgeons for the treatment of battle field massive bleeding and is now recommended in civil massive bleeding in the USA. This product not only contains functional platelets but also plasma with all active clotting factors. Whole blood has been eliminated from the list of blood product available in many developed countries but this strategy needs to be revised for cases like the one presented. In such a case, the issue is not only \( O_2 \) transport and availability but also containing the bleeding for which platelets and fresh plasma is necessary.

**Is the Hb concentration obtained at the time of active gastrointestinal bleeding reliable and accurate?**

**Expert opinion 1**

It is sometimes not reliable because of the haemocoagulation during the time of active bleeding. In addition, the genuine Hb level may be more reliable to be measured after the active bleeding has been stopped.

**Expert opinion 2**

Indeed, Hb concentration can vary at the first 24 hours after the bleeding, leading to some inaccuracy (14). Prior studies showed that Hb can vary after bleeding occurred during surgical procedures (15). However, it is the most used parameter to indicate PRBC transfusion for such patients.

**Expert opinion 3**

The initial Hb was 128 g/L. The normal Hb result is unreliable. Usually the Hb drops subsequently.

**How many units of PRBC should be infused in this patient? (optimal dosage of PRBC)**

**Expert opinion 1**

I would adopt 1–2 pints of packed cell every time.

**Expert opinion 2**

Actually, I would not prescribe a PRBC transfusion unless the patient developed another complication, such as hemorrhagic shock.

**Expert opinion 3**

The follow-up Hb was 74 g/L. The amount of blood transfusion would be 2–4 Taiwan blood units; it is about 1–2 American units to maintain a Hb level of about 80 g/L.

**Conclusions**

Massive hematemesis is not an indication for blood transfusion. A wait-and-see strategy of PRBC transfusion may be considered in a cirrhotic patient. Except for elder patients with cardiovascular or cerebrovascular abnormalities, blood transfusion may not be given until Hb concentration was less than 70 g/L. Instead, if he/she presented with active bleeding and had a Hb concentration of above 80 g/L, an emergency blood transfusion may elevate the portal pressure and induce the re-bleeding events.

**Acknowledgements**

None.

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**References**


doi: 10.21037/amj.2018.08.02

Cite this article as: Bai Z, Guo X, Li H, Yu X, Deng J, Yuen MF, Romeiro FG, Yang SS, Allain JP, Qi X; written on behalf of AME Liver Disease Collaborative Group. Should red blood cell transfusion be immediately given to a cirrhotic patient with active upper gastrointestinal bleeding? AME Med J 2018;3:83.